Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Cobimetinib

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Approves Oral MEK Inhibitor Cobimetinib Histiocytic Neoplasms Led by MSKCC
    FDA Approves Oral MEK Inhibitor Cobimetinib Histiocytic Neoplasms Led by MSKCC

    01 Nov 2022

    // MSKCC

    https://www.mskcc.org/news-releases/fda-approves-oral-mek-inhibitor-cobimetinib-histiocytic-neoplasms-research-led-msk-cancer

    MSKCC
    01 Nov 2022
    Share Share
    Revolution Medicines to Present Interim Data at ENA 2020 Ph 1b/2 Trial RMC-4630
    Revolution Medicines to Present Interim Data at ENA 2020 Ph 1b/2 Trial RMC-4630

    12 Oct 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/10/12/2106773/0/en/Revolution-Medicines-to-Present-Interim-Data-at-ENA-2020-from-Phase-1b-2-Clinical-Trial-Combining-RMC-4630-with-Cobimetinib-for-RAS-Addicted-Solid-Tumors.html

    GLOBENEWSWIRE
    12 Oct 2020
    Share Share
    Roche's phase III IMspire150 study of Tecentriq plus Cotellic & Zelboraf
    Roche's phase III IMspire150 study of Tecentriq plus Cotellic & Zelboraf

    13 Dec 2019

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=119938&sid=2

    PHARMABIZ
    13 Dec 2019
    Share Share
    REVOLUTION Medicines Announces Dosing Patient in RMC-4630-02 with RMC-4630
    REVOLUTION Medicines Announces Dosing Patient in RMC-4630-02 with RMC-4630

    18 Sep 2019

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/revolution-medicines-announces-dosing-of-first-patient-in-rmc-4630-02-a-phase-1b2-trial-combining-rmc-4630-with-a-mek-inhibitor-300919270.html

    PR NEWSWIRE
    18 Sep 2019
    Share Share
    Roche/Exelixis' Cotellic fizzles in pivotal melanoma study
    Roche/Exelixis' Cotellic fizzles in pivotal melanoma study

    21 Jun 2019

    // Natalie Grover ENDPTS

    https://endpts.com/roche-exelixis-cotellic-fizzles-in-pivotal-melanoma-study/

    Natalie Grover ENDPTS
    21 Jun 2019
    Share Share
    Novartis wins key adjuvant Taf/Mek approval in Europe
    Novartis wins key adjuvant Taf/Mek approval in Europe

    29 Aug 2018

    // Phil Taylor PM LIVE

    http://www.pmlive.com/pharma_news/novartis_wins_key_adjuvant_tafmek_approval_in_europe_1250603

    Phil Taylor PM LIVE
    29 Aug 2018
    Share Share